Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;20(2):211-229.
doi: 10.1080/14787210.2021.1949984. Epub 2021 Jul 29.

The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review

Kaeshaelya Thiruchelvam  1   2 , Chia Siang Kow  3   4 , Muhammad Abdul Hadi  5 , Syed Shahzad Hasan  6   7
Affiliations

The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review

Kaeshaelya Thiruchelvam et al. Expert Rev Anti Infect Ther. 2022 Feb.

Abstract

Objective: We systematically reviewed the evidence of published original research to determine the role of remdesivir in the management of patients with COVID-19 and a moderate-to-severe course of illness.

Methods: A systematic search of articles was conducted in scientific databases, with the latest update in May 2021. This paper systematically reviewed the clinical evidence available (randomized controlled trials, compassionate use studies, and case reports) on the use of remdesivir for patients with moderate or severe COVID-19.

Results: A total of eleven studies were included: four studies based on compassionate use of remdesivir, three randomized, double-blind, placebo-controlled, multicentre trials, three randomized, open-label, phase III trials, and one case report. Clinical improvement and mortality rates in patients who used remdesivir varied across studies.

Conclusion: Given the current evidence, there is insufficient data to confidently recommend the use of remdesivir alone for the treatment of adult hospitalized patients with moderate-to-severe COVID-19. However, remdesivir may be considered along with an anti-inflammatory agent in patients with pneumonia, on oxygen support, provided there is close monitoring of clinical and laboratory parameters and adverse events.

Keywords: Adverse events; SARS-CoV-2; critically ill; evidence-based medicine; remdesivir.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Study selection process
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Helmy YA, Fawzy M, Elaswad A, et al. The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. J Clin Med. 2020;9(4):1225. - PMC - PubMed
    1. Abi-Habib MMillions had Risen out of poverty. Coronavirus is pulling them back. The New York Times [Internet]. 2020. Apr 30 [cited 2020 Jun 2]. Available from: https://www.nytimes.com/2020/04/30/world/asia/coronavirus-poverty-unempl...
    1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. - PMC - PubMed
    1. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020Apr1;8(4):420–422. - PMC - PubMed
    1. Murthy S, Gomersall CD, Fowler RA.. Care for critically Ill patients with COVID-19. JAMA. 2020;323(15):1499–1500. - PubMed

Publication types

MeSH terms

LinkOut - more resources